Condition: Non-Small Cell Lung Cancer · Sponsor: Mark Vincent
This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy. The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).
This description comes directly from the study's public registry record.
Mark Vincent, MD · 519-685-8640 · Mark.Vincent@lhsc.on.ca
Daniel Breadner, MD · Daniel.Breadner@lhsc.on.ca
Always discuss trial participation with your own doctor first.
| BC Cancer Agency | Vancouver, British Columbia, Canada | Recruiting |
| Lions Gate Hospital | Vancouver, British Columbia, Canada | Recruiting |
| William Osler Health System | Brampton, Ontario, Canada | Recruiting |
| Hamilton Health Sciences Centre, Juravinski Cancer Centre | Hamilton, Ontario, Canada | Recruiting |
| Grand River Regional Cancer Centre | Kitchener, Ontario, Canada | Recruiting |
| London Regional Cancer Program of the Lawson Health Research Institute | London, Ontario, Canada | Recruiting |
| Durham Regional Cancer Centre, Lakeridge Health | Oshawa, Ontario, Canada | Recruiting |
| The Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
| Sunnybrook Research Institute | Toronto, Ontario, Canada | Recruiting |
| Princess Margaret Hospital | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04335292